CARdiac Function Evaluation in Breast Cancer Patients

Breast Cancer Female Clinical Trial

— CARE-B  

Official title:

Longitudinal Characterisation of Cardiac Function in Recently-diagnosed Breast Cancer Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03266809
• Other study ID #: 188676
• Status: Completed
• Start date: August 1, 2017
• Est. completion date: April 1, 2020

Study information

• Verified date: November 2022
• Source: Swansea University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will investigate the influence of systemic adjuvant/neoadjuvant therapy (SAT: chemotherapy +/- anti-HER2 antibodies (trastuzumab +/- pertuzumab) on heart function/rhythm and cardio-respiratory fitness in recently diagnosed breast cancer patients. In some patients, SAT damages the heart (so-called 'cardiotoxicity') and this can have a serious impact on the patient's quality of life and overall survival. It has also been suggested that anticancer therapies may lead to repolarization abnormalities, QT prolongation and autonomic dysfunction, clinically reflected by an increase in HR and a reduction in heart rate variability (HRV). There is a lack of information in the literature regarding the extent and time-course of changes in cardiac function, cardiac rhythm and cardio-respiratory performance ('fitness') in these patients. Moreover, the differential influences of specific treatment regimes (e.g. SAT or SAT plus radiotherapy) and different chemotherapy drugs on cardio-respiratory performance remain unclear. A better understanding of these issues is the primary aim of this study.

Description:

This study will focus on the following:

1. Cardiac function assessment: The conventional method for assessing heart function (in terms of 'ejection fraction') in patients being treated for cancer uses nuclear medicine (MUGA scan). MRI can also provide this information but it is not typically used for cardiac function assessment in these patients. MUGA scans are typically performed before chemotherapy in selected patients at higher risk of cardiotoxicity and in all cases before starting anti-HER2 antibody treatment (trastuzumab, pertuzumab). Patients receiving anti-HER2 antibody treatment receive repeat cardiac assessments at 3-4 month intervals until the completion of treatment - it is not practical or cost-effective to scan more frequently. This study will determine whether an alternative and inexpensive method for monitoring heart function (Impedance Cardiography, ICG) can adequately quantify changes in ejection fraction during treatment. If it can, then this technique could be used more frequently during and following treatment, with the aim of determining the treatment stages during which the heart is most at risk of damage. The ability of ICG to dynamically characterise a relatively rapid decline in cardiac function in breast cancer patients has not been established. Neither has its performance been compared with MRI or MUGA in this population. This study will investigate whether ICG is a sufficiently accurate and reliable alternative to MRI/MUGA for determining cardiac dysfunction during and following cancer treatment.

2. Cardiac rhythm and autonomic function assessment: Heart rate variability (HRV) reflects the modulation of the heart by the autonomic nervous system, and it can be quantified using several different methods based on analysis of the temporal changes between successive heartbeats. The development of autonomic dysfunction in breast cancer patients has been shown in a few small clinical studies, but the majority of these studies have considered HR rather than HRV, which is a much less robust measure of autonomic function. The few studies that have used HRV analysis have demonstrated significant reductions in HRV following the completion of anthracycline-based therapy. Previous research on other ECG markers (e.g. QT and QRS duration) in breast cancer patients has mainly focused on anthracycline-based regimes; the influence of trastuzumab treatment on ECG makers has been evaluated in only two studies to date. It is still not clear whether these changes can predict subsequent LV dysfunction although QT variability is a possible marker of myocardial contractility and has been shown to increase as a result of anthracycline therapy in breast cancer patients. This study aims to characterise the impact of different treatment regimes on the temporal properties of the ECG and will compare beat-to-beat QT variability and beat-to-beat T wave variability in breast cancer patients receiving a range of treatment regimes.

3. Body composition and cardiorespiratory fitness assessment: This study also aims to characterise the patterns of change in body composition, physical activity and cardiorespiratory fitness in breast cancer patients. The study will examine whether these modifiable factors might influence a patient's susceptibility to cardiac changes during treatment and, in turn, how these factors are affected by treatment. Of particular interest, it has been suggested that cardiorespiratory fitness (measured by the rate of oxygen uptake) is impaired in breast cancer patients compared to healthy controls, even seven years following the completion of treatment. Oxygen-uptake analysis will be performed in this study to explore possible compensatory mechanisms for abnormal pathology- or treatment-induced cardiac function in breast cancer patients. Fitness, physical activity and body composition will be assessed quantitatively using a range of objective techniques, including cardiopulmonary exercise testing on a cycle ergometer (fitness) with breath-by-breath gas analysis (cardiorespiratory function), accelerometery (activity levels) and DEXA radiography scans (body composition).

The main research questions in this study are:

1. Is the CARE-B protocol practically feasible and tolerable to early-stage breast cancer patients?

2. What is the level of agreement between cardiac (ventricular) function determined using cardiac MRI, MUGA and Impedance Cardiography in breast cancer patients receiving SAT?

3. Is cardiac rhythm (heart rate and QT variability) altered in breast cancer patients receiving SAT?

4. Is oxygen transport and oxygen uptake into tissue altered in breast cancer patients receiving SAT?

5. Does a patient's baseline physical activity, fitness and body composition affect their susceptibilities to treatment-induced cardio-respiratory problems?

6. Does a patient's physical activity, physical fitness and body composition change appreciably during SAT in these patients?

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: April 1, 2020
• Est. primary completion date: September 28, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Eligible participants will be women aged 18 years or over with the following characteristics:

• Early invasive breast cancer (stage I-III)

• Due to start adjuvant or neoadjuvant therapy including either anthracycline-based chemotherapy, or chemotherapy + trastuzumab +/- pertuzumab

• WHO performance status <=2

• Absence of major cardiovascular or chronic respiratory problems, or other conditions that in the opinion of the clinician would contraindicate the use of physical exercise assessments

• Absence of contraindications for MRI scans, as listed in Paragraph 3.3. Patients unsuitable or unwilling to undergo MRI scans will be eligible for the study only if they are planned to receive trastuzumab, since this will include LVEF monitoring with MUGA scans or echocardiograms as part of routine care

• Provision of signed informed consent.

Exclusion Criteria:

• Presence of major cardiovascular or chronic respiratory problems, or other conditions that in the opinion of the clinician would contraindicate the use of treadmill exercise assessments

• Presence of contraindications for MRI scans:

• Internal electronic devices such as neurostimulators or defibrillators

• Replacement heart valve

• Cardiac pacemaker

• Intracranial vessel clips

• Internal ear implant

• Claustrophobia

• Pregnancy.

MRI scans will be requested by a clinician after the exclusion of the above contraindications. Patients unsuitable or unwilling to undergo MRI scans will be eligible for the study only if they are planned to receive trastuzumab, since this includes LVEF monitoring with MUGA scans or echocardiograms as part of routine care.

Related Conditions & MeSH terms

• Breast Cancer Female
• Breast Neoplasms

Locations

Country	Name	City	State
United Kingdom	Singleton Hospital	Swansea	Wales

Sponsors (2)

Lead Sponsor	Collaborator
Swansea University	Abertawe Bro Morgannwg University Health Board

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cardiac Function (stroke volume or ejection fraction)	Cardiac function during/following treatment in breast cancer patients.	At completion of treatment, an average of 13 months
Primary	Cardiac Rhythm (heart rate variability)	Cardiac rhythm during/following treatment in breast cancer patients.	At completion of treatment, an average of 13 months
Secondary	Physical activity level (accelerometer-based activity level 'counts')	Physical activity level during/following treatment in breast cancer patients.	At completion of treatment, an average of 13 months
Secondary	Cardiorespiratory function (rate of respiratory oxygen uptake)	Cardiorespiratory function during/following treatment in breast cancer patients.	At completion of treatment, an average of 13 months
Secondary	Body mass composition (from DEXA scan)	Body fat mass and fat-free mass, and bone mineral density	At completion of treatment, an average of 13 months